Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
Compounds for proteasome enzyme inhibition
No-Receipt date
2014-02933 - 06/10/2014
No-Filing date
20140401999 - 06/10/2014
No-Granting date
3084468 - 13/10/2014
No-EPO application date
08164241.5 - 09/05/2005
No-EPO granting date
2030981 - 09/07/2014
Gazette No-Publication date of application
-
Gazette No-Publication date of granted patent
10/2014 - 21/11/2014
Expiration date
10/05/2025
Kind of title
Validation of European Patent
Legal status
NOT VALID
Priorities
US569885 P10/05/2004/US
US610040 P14/09/2004/US
US634366 P07/12/2004/US
Active Substance of Supplementary Certificates
-
IPC Classification
Ipc Class
C07K 5/087
C07K 5/08
C07K 5/078
C07K 5/062
C07K 5/027
C07D 413/12
C07D 409/12
C07D 303/32
A61K 38/06
A61K 31/335
Related Documents
Related Titles
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
552912
ONYX THERAPEUTICS, INC.
249 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
UNITED STATES OF AMERICA (USA)
Inventors
Code
Firstname
Surname
1331513
SMYTH, MARK S.
1331514
LAIDIG, GUY J.
1331515
BORCHARDT, RONALD T.
1331516
BUNIN, BARRY A.
1331517
CREWS, CRAIG M.
1331518
MUSSER, JOHN H.
1331519
SHENK, KEVIN D.
1331520
RADEL, PEGGY A.
Representatives
Code
Firstname
Surname
Address
Town
Zip
1349
ELENI
PAPAKONSTANTINOU
KOUMPARI 2
ATHINA (ATTIKIS)
10674
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
4007
ELENI
PAPAKONSTANTINOU
KOUMPARI 2
ATHINA (ATTIKIS)
10674
GREECE
Owners History
Title Instruments
Date
Operation
Descreption
12/9/2020 12:00:00 AM
Έκπτωση Κύριων Τίτλων (79602)
ΕΚΠΤΩΣΕΙΣ 11/2020 Αρ. Πρωτ. ΓΔ 2049 / 09.12.2020
Payments history
15 renewals have been done
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).